I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on April 24, 200

Frank C. Eisenschenk, Ph.D., Patent Attorney

ELECTION UNDER 35 U.S.C. § 121 Patent Application Docket No. INN.133

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Marianne Dibrino

Art Unit

1646

**Applicants** 

Alessandro Moretta, Mariella Della Chiesa

Serial No.

10/563,045

Filed

December 30, 2005

Conf. No.

6062

For

Compositions and Methods for Regulating NK Cell Activity

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

## ELECTION UNDER 35 U.S.C. § 121 AND SUPPLEMENTAL PRELIMINARY AMENDMENT

Sir:

Applicants request that the period for response be extended one month through and including April 24, 2009, the fees for which have been paid at the time this Election was filed.

In response to the written Restriction Requirement dated February 24, 2009 in the aboveidentified patent application, Applicants hereby elect to prosecute the invention of Group I (claims 56-59), without traverse. As the species, Applicants hereby elect DF200 as the species of the isolated antibody; IL-2 as the additional component; a detectable moiety; and the KIR receptors bind to KIR2DL1 and KIR2DL2/3 and neutralizes KIR mediated inhibition of NK cell cytotoxicity.

Prior to examination, Applicants respectfully request that the subject application be amended as follows: